Targeting Cancer at the Intersection of Signaling and Epigenetics

Literature Cited

1. Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M et al. 2017. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Res 77:6651–66
   [Google Scholar]
2. Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M et al. 2017. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130:732–41
   [Google Scholar]
3. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M et al. 2014. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:278–82
   [Google Scholar]
4. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ et al. 2016. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol. Cancer Res. 14:324–31
   [Google Scholar]
5. Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C et al. 2015. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. PNAS 112:232–37
   [Google Scholar]
6. Baylin SB, Jones PA 2016. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol. 1:a019505
   [Google Scholar]
7. Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M et al. 2015. mTOR kinase inhbitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget 6:2088–100
   [Google Scholar]
8. Beck S, Bernstein BE, Campbell RM, Costello JF, Dhanak D et al. 2012. A blueprint for an international cancer epigenome consortium: a report from the AACR Cancer Epigenome Task Force. Cancer Res 2:6319–24
   [Google Scholar]
9. Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C et al. 2016. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase I study. Lancet Haematol 3:e186–95
   [Google Scholar]
10. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E et al. 2003. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323–35
    [Google Scholar]
11. Cancer Genome Atlas Res. Netw. 2013. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45:1113–20
    [Google Scholar]
12. Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP et al. 2013. The HDAC inhibitor, MPT0E028, enhances erolotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis 4:e810
    [Google Scholar]
13. Dawson MA, Kouzarides T 2012. Cancer epigenetics: from mechanism to therapy. Cell 150:12–27
    [Google Scholar]
14. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904–17
    [Google Scholar]
15. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H et al. 2014. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514:247–51
    [Google Scholar]
16. Dong LH, Cheng S, Zheng Z, Wang L, Shen Y et al. 2013. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J. Hematol. Oncol. 6:53
    [Google Scholar]
17. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P et al. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39
    [Google Scholar]
18. Evrot E, Ebel N, Romanet V, Roelli C, Andraos R et al. 2013. JAK1/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in pre-clinical mouse models of JAK2^V617F-driven disease. Clin. Cancer Res. 19:6230–41
    [Google Scholar]
19. Flavahan WA, Gaskell E, Bernstein B 2017. Epigenetic plasticity and the hallmarks of cancer. Science 357:eaal2380
    [Google Scholar]
20. Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S et al. 2015. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525:538–42
    [Google Scholar]
21. French CA, Rahman S, Walsh EM, Kuhnle S, Grayson AR et al. 2014. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 4:928–41
    [Google Scholar]
22. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ et al. 2008. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27:2237–42
    [Google Scholar]
23. Fruman DA, Rommel C 2014. PI3K and cancer: lessons, challenges, and opportunities. Nat. Rev. Drug Discov. 13:140–56
    [Google Scholar]
24. Garraway LA, Lander ES 2013. Lessons from the cancer genome. Cell 153:17–37
    [Google Scholar]
25. Gray J, Haura E, Chiappori A, Tanvetyanon T, Williams C et al. 2014. A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin. Cancer Res. 20:1644–55
    [Google Scholar]
26. Hanahan D, Weinberg RA 2000. The hallmarks of cancer. Cell 100:57–70
    [Google Scholar]
27. Hanahan D, Weinberg RA 2011. Hallmarks of cancer: the next generation. Cell 144:646–74
    [Google Scholar]
28. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M et al. 2012. A landscape of driver mutations in melanoma. Cell 150:251–63
    [Google Scholar]
29. Hug BA, Lazar MA 2004. ETO interacting proteins. Oncogene 23:4270–74
    [Google Scholar]
30. Jones PA, Issa JP, Baylin SB 2016. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17:630–41
    [Google Scholar]
31. Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N et al. 2017. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep 21:3398–405
    [Google Scholar]
32. Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A et al. 2015. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21:1491–96
    [Google Scholar]
33. Kim KH, Roberts CW 2016. Targeting EZH2 in cancer. Nat. Med. 22:128–34
    [Google Scholar]
34. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ et al. 2013. Durable tumor regression in genetically altered malignant rhaboid tumors by inhibition of methyltransferase EZH2. PNAS 110:7922–27
    [Google Scholar]
35. Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK et al. 2017. Mutated chromatin regulatory factors as tumor drivers in cancer. Cancer Res 77:227–33
    [Google Scholar]
36. Kotian S, Zhang L, Boufraqech M, Gaskins K, Gara SK et al. 2017. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. Clin. Cancer Res. 23:5044–54
    [Google Scholar]
37. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M et al. 2017. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78–83
    [Google Scholar]
38. Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J et al. 2016. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep 16:1273–86
    [Google Scholar]
39. Landsberg DJ, Ramchandren R, Hafeez A, Gharavi R, Chander T 2016. Open-label, phase 2 study to evaluate the efficacy and safety of CUDC-907 in patients with relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC alterations. Blood 128:5422
    [Google Scholar]
40. Leder A, Leder P 1975. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5:319–22
    [Google Scholar]
41. Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN et al. 2014. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46:1227–32
    [Google Scholar]
42. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE et al. 2012. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 119:4017–25
    [Google Scholar]
43. Li Y, Seto E 2016. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. 6:a026831
    [Google Scholar]
44. Licht JD. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660–79
    [Google Scholar]
45. Lock R, Ingraham R, Maertens O, Miller AL, Weledji N et al. 2016. Co-targeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J. Clin. Investig. 126:2181–90
    [Google Scholar]
46. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA et al. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 53:320–34
    [Google Scholar]
47. Luo J, Solimini NL, Elledge SJ 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823–37
    [Google Scholar]
48. Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S et al. 2010. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16:141–53
    [Google Scholar]
49. Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S et al. 2017. mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discov 7:1450–63
    [Google Scholar]
50. Malone CF, Fromm JA, Maertens O, De Raedt T, Ingraham R, Cichowski K 2014. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov 4:1062–73
    [Google Scholar]
51. Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J et al. 2016. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164:293–309
    [Google Scholar]
52. Massard C, Soria J, Stathis A, Delord J, Awada A et al. 2016. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. EJC 69:S2–3
    [Google Scholar]
53. Matkar S, Sharma P, Gao S, Gurung B, Katona BW et al. 2015. An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO/c-Myc axis. Cancer Cell 28:472–85
    [Google Scholar]
54. Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S et al. 2015. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 21:1163–71
    [Google Scholar]
55. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–12
    [Google Scholar]
56. McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM et al. 2018. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J. Clin. Investig. 128:789–804
    [Google Scholar]
57. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE et al. 2010. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nat. Med. 16:286–94
    [Google Scholar]
58. Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ et al. 2017. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget 8:14017–28
    [Google Scholar]
59. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J et al. 2010. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42:181–85
    [Google Scholar]
60. Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J et al. 2017. BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death Dis 8:e2982
    [Google Scholar]
61. New M, Olzcha H, La Thangue NB 2012. HDAC-inhibitor-based therapies: Can we interpret the code. Mol. Oncol. 6:637–56
    [Google Scholar]
62. Newbold A, Falkenberg KJ, Prince HM, Johnstone RW 2016. How do tumor cells respond to HDAC inhibition. FEBS J 283:4032–46
    [Google Scholar]
63. Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC et al. 2012. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2:e69
    [Google Scholar]
64. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A et al. 2013. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res. 19:6882–90
    [Google Scholar]
65. Oki Y, Kelly KR, Flinn IW, Patel MR, Gharavi R et al. 2017. CUDC-907 In relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial. Haematologica 102:1923–30
    [Google Scholar]
66. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM et al. 2007. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25:3109–15
    [Google Scholar]
67. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS et al. 2016. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7:67521–31
    [Google Scholar]
68. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T et al. 2017. Personalized in vitro and in vivo cancer models. Cancer Discov 7:462–77
    [Google Scholar]
69. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P 2013. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14:765–80
    [Google Scholar]
70. Popovic R, Licht JD 2012. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2:405–13
    [Google Scholar]
71. Qian C, Lai CJ, Bao R, Wang DG, Wang J et al. 2012. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res. 18:4104–13
    [Google Scholar]
72. Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S 2014. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin. Cancer Res. 20:4849–60
    [Google Scholar]
73. Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, Kumar S 2014. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leuk. Res. 38:1358–66
    [Google Scholar]
74. Rathert P, Roth M, Neumann T, Muerdter F, Roe JS et al. 2015. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525:543–47
    [Google Scholar]
75. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B et al. 1996. Second generation hybrid polar compounds as potent inducers of transformed cell differentiation. PNAS 93:5705–8
    [Google Scholar]
76. Riggs MG, Whittaker RG, Neumann JR, Ingram VM 1977. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462–64
    [Google Scholar]
77. Roadmap Epigenom. Consort. 2015. Integrative analysis of 111 reference human epigenomes. Nature 518:317–30
    [Google Scholar]
78. Sauvageau M, Sauvageau G 2010. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7:299–313
    [Google Scholar]
79. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS et al. 2015. Feedback suppression of PI3Kα signaling in PTEN mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 27:109–22
    [Google Scholar]
80. Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R et al. 2016. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov 6:1248–57
    [Google Scholar]
81. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH et al. 2011. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547–57
    [Google Scholar]
82. Shen H, Laird PW 2013. Interplay between the cancer genome and epigenome. Cell 153:38–55
    [Google Scholar]
83. Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS et al. 2017. Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia. Cancer Discov 7:494–505
    [Google Scholar]
84. Shu S, Polyak K 2016. BET bromodomain proteins as cancer therapeutic targets. Cold Spring Harb. Symp. Quant. Biol. 81:123–29
    [Google Scholar]
85. Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J 2017. Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation. Mol. Cancer Ther. 16:2008–21
    [Google Scholar]
86. Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O et al. 2017. Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence. Cell Rep 21:2796–812
    [Google Scholar]
87. Stathis A, Bertoni F 2018. BET proteins as targets for anticancer treatment. Cancer Discov 8:24–36
    [Google Scholar]
88. Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C et al. 2015. Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy. Cancer Cell 27:837–51
    [Google Scholar]
89. Stuhlmiller TJ, Miller SM, Zawistowki JS, Nakamura K, Beltran AS et al. 2015. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep 11:390–404
    [Google Scholar]
90. Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME et al. 2017. Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers. Mol. Cancer Ther. 16:285–99
    [Google Scholar]
91. Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N et al. 2017. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171:1284–300.e21
    [Google Scholar]
92. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE et al. 2012. Functional genomics identifies therapeutic targets for MYC-driven cancer. PNAS 109:9545–50
    [Google Scholar]
93. Urbanucci A, Barfeld SJ, Kytola V, Itkonen HM, Coleman IM et al. 2017. Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer. Cell Rep 19:2045–59
    [Google Scholar]
94. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–29
    [Google Scholar]
95. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K et al. 2009. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114:5024–33
    [Google Scholar]
96. West AC, Johnstone RW 2014. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Investig. 124:30–39
    [Google Scholar]
97. Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE et al. 2017. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 67:5–18.e19
    [Google Scholar]
98. Xie H, Peng C, Huang J, Li BE, Smith EC et al. 2016. Chronic myelogenous leukemia–initiating cells require polycomb group protein EZH2. Cancer Discov 6:1237–47
    [Google Scholar]
99. Xu K, Wu ZJ, Groner AC, He HH, Cai C et al. 2012. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338:1465–69
    [Google Scholar]
100. Xu Y, Vakoc CR 2017. Targeting cancer cells with BET bromodomain inhibitors. Cold Spring Harb. Perspect. Med. 7:a026674
     [Google Scholar]
101. Yang EG, Mustafa N, Tan EC, Poulsen A, Ramanujulu PM et al. 2016. Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines. J. Med. Chem. 59:188233–62
     [Google Scholar]
102. Yang L, Zhang Y, Shan W, Hu Z, Yuan J et al. 2017. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med. 9:eaal1645
     [Google Scholar]
103. Yao L, Mustafa N, Tan EC, Poulsen A, Singh P et al. 2017. Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat. J. Med. Chem. 60:8336–57
     [Google Scholar]
104. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E et al. 2008. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 36:443–50
     [Google Scholar]
105. You JS, Jones PA 2012. Cancer genetics and epigenetics: Two sides of the same coin. Cancer Cell 22:9–20
     [Google Scholar]
106. Younes A, Berdeja JG, Patel MR, Kelly KR, Flinn IW et al. 2015. Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: initial assessment of patients with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL), including double expressor (DE) lymphoma. Blood 126:257
     [Google Scholar]
107. Younes A, Samad N 2011. Utility of mTOR inhibition in hematologic malignancies. Oncologist 16:730–41
     [Google Scholar]
108. Zhang M, Wang Y, Jones S, Sausen M, McMahon K et al. 2014. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 46:1170–72
     [Google Scholar]
109. Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A et al. 2015. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investig. New Drugs 33:1040–47
     [Google Scholar]
110. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478:524–28
     [Google Scholar]